ORTHO TRI CYCLEN Lo

×

Overview

What is ORTHO TRI CYCLEN Lo?

ORTHO TRI-CYCLEN Lo is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime, (17α)-(+)-) and ethinyl estradiol is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol).

What does ORTHO TRI CYCLEN Lo look like?

What are the available doses of ORTHO TRI CYCLEN Lo?

ORTHO TRI-CYCLEN Lo consists of 28 round, biconvex, coated tablets in the following order ():

What should I talk to my health care provider before I take ORTHO TRI CYCLEN Lo?

Nursing mothers: Not recommended; can decrease milk production. ()

How should I use ORTHO TRI CYCLEN Lo?

ORTHO TRI-CYCLEN Lo is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. ()

ORTHO TRI-CYCLEN Lo is dispensed in either a DIALPAK Tablet dispenser or a VERIDATE Tablet Dispenser . ORTHO TRI-CYCLEN Lo may be started using either a Day 1 start or a Sunday start (see ). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.

What interacts with ORTHO TRI CYCLEN Lo?

Sorry No Records found

What are the warnings of ORTHO TRI CYCLEN Lo?

Sorry No Records found

What are the precautions of ORTHO TRI CYCLEN Lo?

Sorry No Records found

What are the side effects of ORTHO TRI CYCLEN Lo?

Sorry No records found

What should I look out for while using ORTHO TRI CYCLEN Lo?

Do not prescribe ORTHO TRI-CYCLEN Lo to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke .

What might happen if I take too much ORTHO TRI CYCLEN Lo?

There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.

How should I store and handle ORTHO TRI CYCLEN Lo?

Midodrine Hydrochloride Tablets, USP, for oral administration, are available asEEStore at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. FOR YOUR PROTECTION:To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or . Midodrine Hydrochloride Tablets, USP, for oral administration, are available asEEStore at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. FOR YOUR PROTECTION:To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or . Midodrine Hydrochloride Tablets, USP, for oral administration, are available asEEStore at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. FOR YOUR PROTECTION:To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or . Midodrine Hydrochloride Tablets, USP, for oral administration, are available asEEStore at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. FOR YOUR PROTECTION:To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or . Midodrine Hydrochloride Tablets, USP, for oral administration, are available asEEStore at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. FOR YOUR PROTECTION:To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or . Midodrine Hydrochloride Tablets, USP, for oral administration, are available asEEStore at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. FOR YOUR PROTECTION:To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or .

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Non-Clinical Toxicology

Do not prescribe ORTHO TRI-CYCLEN Lo to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke .

When administered concomitantly with midodrine hydrochloride, cardiac glycosides may enhance or precipitate bradycardia, A.V. block or arrhythmia.

The risk of hypertension increases with concomitant administration of drugs that increase blood pressure (phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, or droxidopa). Avoid concomitant use of drugs that increase blood pressure. If concomitant use cannot be avoided, monitor blood pressure closely.

Avoid use of MAO inhibitors or linezolid with midodrine.

Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. The potential for supine hypertension should be carefully monitored in these patients and may be minimized by either reducing the dose of fludrocortisone acetate or decreasing the salt intake prior to initiation of treatment with midodrine hydrochloride. Alpha-adrenergic blocking agents, such as prazosin, terazosin and doxazosin, can antagonize the effects of midodrine hydrochloride.

Thromboembolic Disorders and Other Vascular Problems:

Liver disease:

High blood pressure:

Carbohydrate and lipid metabolic effects:

Headache:

Bleeding Irregularities and Amenorrhea:

The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:

Adverse reactions commonly reported by COC users are:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Disclaimer: